Literature DB >> 17259924

Fenretinide and risk reduction of second breast cancer.

Andrea Decensi1, Silvia Zanardi, Alessandra Argusti, Bernardo Bonanni, Alberto Costa, Umberto Veronesi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17259924     DOI： 10.1038/ncponc0735

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


× No keyword cloud information.
  8 in total

1.  Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment.

Authors:  Konstantin Petrukhin
Journal:  Drug Discov Today Ther Strateg       Date:  2013

Review 2.  Retinol as electron carrier in redox signaling, a new frontier in vitamin A research.

Authors:  Ulrich Hammerling
Journal:  Hepatobiliary Surg Nutr       Date:  2016-02       Impact factor: 7.293

Review 3.  The mitochondrial PKCδ/retinol signal complex exerts real-time control on energy homeostasis.

Authors:  Youn-Kyung Kim; Ulrich Hammerling
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-01-10       Impact factor: 4.698

Review 4.  Novel therapeutics for Stargardt disease.

Authors:  Louise J Lu; Ji Liu; Ron A Adelman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-11       Impact factor: 3.117

5.  Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1.

Authors:  Yong Zhong Xu; Mitra Heravi; Thusanth Thuraisingam; Sergio Di Marco; Thierry Muanza; Danuta Radzioch
Journal:  Mol Cancer       Date:  2010-08-05       Impact factor: 27.401

6.  A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis.

Authors:  Nicoleta Dobri; Qiong Qin; Jian Kong; Kazunori Yamamoto; Zhao Liu; Gennadiy Moiseyev; Jian-Xing Ma; Rando Allikmets; Janet R Sparrow; Konstantin Petrukhin
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

7.  During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.

Authors:  Marcela D Salazar; Maya Ratnam; Mugdha Patki; Ivana Kisovic; Robert Trumbly; Mohamed Iman; Manohar Ratnam
Journal:  Breast Cancer Res       Date:  2011-02-07       Impact factor: 6.466

8.  Disruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acid.

Authors:  Giulia Somenzi; Giusy Sala; Stefano Rossetti; MingQiang Ren; Riccardo Ghidoni; Nicoletta Sacchi
Journal:  PLoS One       Date:  2007-09-05       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.